Investors / stance tracking
What Dan Rasmussen is saying
FollowFollowingUnfollowFounder, Verdad Capital
6 dated public stances tracked since 2019-05-17, most recently 2026-10-16. Each line carries the date and the venue it came from; quotation marks mean verbatim. Methodology.
The stances below are c8alpha's editorial distillation of Dan Rasmussen's public commentary — television, podcasts, and interviews — compiled by automated transcript analysis and dated to the episode they came from. They may lag the speaker's current view and may contain extraction errors. Text in quotation marks is verbatim from the episode; everything else is our paraphrase. Dan Rasmussen is not affiliated with c8alpha and has not endorsed this page. Nothing here is investment advice.
Think we got something wrong? Report a misattribution — we correct it or take it down.
6
tracked stances
6
themes
0
side flips
2026-10-16
last heard
Most-argued themes
| Theme | Stances | Lean | Mix | Last |
|---|---|---|---|---|
| BIOTECH STOCKS IN MOMENTUM-POSITIVE THERAPEUTIC CATEGORIES | 1 | 1 bullish | 2026-02-24 | |
| BIOTECH STOCKS WITH HIGH SPECIALIST FUND OWNERSHIP | 1 | 1 bullish | 2026-02-24 | |
| HIGH SHORT INTEREST / HIGH BORROW COST BIOTECH STOCKS | 1 | 1 bearish | 2026-02-24 | |
| LEVERED SMALL-CAP VALUE EQUITIES | 1 | 1 bullish | 2019-05-17 | |
| PRIVATE EQUITY (AS ASSET CLASS) | 1 | 1 bearish | 2026-02-24 | |
| SK | 1 | 1 bullish | 2026-10-16 |
Tracked stances
bullish / bearish is a view they argued; owns / short is a position they said they hold.
2026-10-16
SK
bullish
CNBC (uncut) · uncut_tv
Korean non-tech stocks trade at roughly 8x earnings — half the valuation of the cheapest US quintile — and are re-rating as Korea's 2024 Value Up corporate governance program (modeled on Japan's successful 2023 reforms) forces family-controlled companies to…
“you can buy deep value companies at about half the valuation in Korea that you can in the United States”
CNBC uncut 2026-10-16 13:01 ET (30 min)
2026-02-24
BIOTECH STOCKS WITH HIGH SPECIALIST FUND OWNERSHIP
bullish
Yet Another Value Podcast · video
Biotech companies owned by multiple specialist funds (>50% portfolio in biotech) deliver higher risk-adjusted returns because specialist consensus functions as a quality filter for underlying science and acquisition candidacy, effects that persist over months
“the consensus is the signal. You don't want your biotech manager to have independent opinions”
Investing in Biotech with Verdad Capital
2026-02-24
BIOTECH STOCKS IN MOMENTUM-POSITIVE THERAPEUTIC CATEGORIES
bullish
Yet Another Value Podcast · video
Biotech companies in therapeutically similar peer groups exhibit positive price momentum clustering because thematic investor flows, shared target validation, and macro sentiment toward a category drive correlated returns that persist beyond individual trial…
“as long as people like obesity drugs, I want to own obesity and as long as they don't like it, I don't want to own it”
Investing in Biotech with Verdad Capital
2026-02-24
HIGH SHORT INTEREST / HIGH BORROW COST BIOTECH STOCKS
bearish
Yet Another Value Podcast · video
Biotech stocks with the highest short interest and borrow costs consistently produce the worst returns because elevated short interest reflects broadly-recognized fraud risk or scientific failure that the market has already identified
“the stuff with really high borrow cost and really high short interest just does terribly”
Investing in Biotech with Verdad Capital
2026-02-24
PRIVATE EQUITY (AS ASSET CLASS)
bearish
Yet Another Value Podcast · video
Private equity is in a valuation bubble driven by consensus overoptimism, a non-consensus call Verdad has held for years that is now being validated by market events
“private equity is in a bubble. Stay the f out of it”
Investing in Biotech with Verdad Capital
2019-05-17
LEVERED SMALL-CAP VALUE EQUITIES
bullish
The Acquirers Podcast · video
Replicating private equity's 1980–2006 formula in public markets — buying companies that are small (~$200M market cap), cheap (<7x EV/EBITDA), and levered (~65% net debt to enterprise value) — captures the same gross alpha PE earned (≈12%/yr) without the fee…
“buy cheap small stocks with debt... small value on steroids”
Private Equity in Public: Verdad's Dan Rasmussen talks to Tobias Carlisle on The Acquirers Podcast
Idea Scout Weekly
Every Sunday: who said what across the tape we track — 1766 voices, 5,177 episodes and articles — with side-flips and points of disagreement called out. Free. How we track it.
Free · double opt-in · unsubscribe in one click